Abstract
Objectives: To assess the feasibility of using a novel ultrasensitive bright-field in situ hybridization approach (BRISH) to evaluate k and l immunoglobulin messenger RNA (mRNA) expression in situ in B-cell non-Hodgkin lymphoma (NHL). Methods: A series of 110 semiconsecutive clinical cases evaluated for lymphoma with historic flow cytometric (FCM) results were assessed with BRISH. Results: BRISH light chain restriction (LCR) results were concordant with FCM in 108 (99%) of 109 evaluable cases. Additional small B-cell lymphoma cohorts were successfully evaluated. Conclusions: BRISH analysis of k and l immunoglobulin mRNA expression is a sensitive tool for establishing LCR in B-cell NHL when FCM results are not available.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 736-746 |
| Number of pages | 11 |
| Journal | American Journal of Clinical Pathology |
| Volume | 140 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2013 |
Keywords
- B-cell clonality
- B-cell lymphoma
- BRISH
- CISH
- In situ hybridization
- RNAscope
ASJC Scopus subject areas
- Pathology and Forensic Medicine
Fingerprint
Dive into the research topics of 'Ultrasensitive RNA in situ hybridization for detection of restricted clonal expression of low-abundance immunoglobulin light chain mRNA in B-cell lymphoproliferative disorders'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS